A Phase 3 interventional study of Pitavastatin and Pravastatin in Hypercholesterolemia or Combined Dyslipidemia, sponsored by Kowa Research Europe. Completed at 62 sites in 5 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2010-03-16.
Sponsored by Kowa Research Europe (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 2nd largest by enrollment, is one of 5 that started in 2005, is one of 9 in phase 3, and was the 4th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2005.
This study's enrollment of 962 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 200 across the 19 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kowa Research Europe, one of the names counted as Kowa Company, Ltd.. Under that name alone:
Kowa Research Europe is the lead sponsor of 10 studies on the registry; none are open to participants now.
11 studies in Hypercholesterolemia by Kowa Company, Ltd.: 1 open now, 1 under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Hypercholesterolemia by Kowa Company, Ltd., this one is the 2nd largest by enrollment, is one of 4 that started in 2005, is one of 10 in phase 3, and was the 3rd registered.
Kowa Company, Ltd.’s Hypercholesterolemia studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Kowa Company, Ltd.’s 11 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of pitavastatin with that of pravastatin in elderly patients
Following a wash-out dietary lead-in period, patients will receive either Preavastatin or Pitavastatin during 12 weeks, in order to establish the efficacy of pitavastatin in reducing cholesterol levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pitavastatin 1 mg once daily
Drug: Pitavastatin
Pravastatin 10 mg once daily
Drug: Pravastatin
Pitavastatin 2 mg once daily
Drug: Pitavastatin
Pravastatin 20 mg once daily
Drug: Pravastatin
Pitavastatin 4 mg once daily
Drug: Pitavastatin
Pravastatin 40 mg once daily
Drug: Pravastatin
Percent Change From Baseline in LDL-C
Percent change from baseline in low density cholesterol (LDL-C)
Time frame: Baseline to 12 weeks
Percent Change From Baseline in TC
Percent change from baseline in total cholesterol (TC)
Time frame: Baseline to 12 weeks
| Milestone | Pitavastatin 1 mg | Pravastatin 10 mg | Pitavastatin 2 mg | Pravastatin 20 mg | Pitavastatin 4 mg | Pravastatin 40 mg |
|---|---|---|---|---|---|---|
| Started | 209 | 108 | 226 | 99 | 216 | 104 |
| Safety population | 207 | 103 | 224 | 96 | 210 | 102 |
| Completed | 188 | 89 | 208 | 88 | 194 | 95 |
| Not completed | 21 | 19 | 18 | 11 | 22 | 9 |
Percent change from baseline in low density cholesterol (LDL-C)
| Percent change | Pitavastatin 1 mg | Pravastatin 10 mg | Pitavastatin 2 mg | Pravastatin 20 mg | Pitavastatin 4 mg | Pravastatin 40 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in LDL-C | -31.43 ± 11.833 | -22.41 ± 14.051 | -38.99 ± 13.069 | -28.83 ± 11.054 | -44.31 ± 13.695 | -33.98 ± 14.299 |
Percent change from baseline in total cholesterol (TC)
| Percent change | Pitavastatin 1 mg | Pravastatin 10 mg | Pitavastatin 2 mg | Pravastatin 20 mg | Pitavastatin 4 mg | Pravastatin 40 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in TC | -22.19 ± 8.899 | -15.34 ± 11.037 | -26.68 ± 9.429 | -20.61 ± 8.426 | -30.75 ± 10.461 | -24.07 ± 10.907 |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pitavastatin 1 mg | — | — | — |
| Pravastatin 10 mg | — | — | — |
| Pitavastatin 2 mg | — | — | — |
| Pravastatin 20 mg | — | — | — |
| Pitavastatin 4 mg | — | — | — |
| Pravastatin 40 mg | — | — | — |
| Event | Pitavastatin 1 mg | Pravastatin 10 mg | Pitavastatin 2 mg | Pravastatin 20 mg | Pitavastatin 4 mg | Pravastatin 40 mg |
|---|---|---|---|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/207 | 0/103 | 0/224 | 1/96 | 0/210 | 0/102 |
| Acute myocardial infarctionCardiac disorders | 0/207 | 0/103 | 0/224 | 0/96 | 0/210 | 1/102 |
| CholecystitisHepatobiliary disorders | 0/207 | 0/103 | 0/224 | 0/96 | 0/210 | 1/102 |
| CholelithiasisHepatobiliary disorders | 0/207 | 0/103 | 0/224 | 0/96 | 0/210 | 1/102 |
| Bleeding varicose veinVascular disorders | 0/207 | 0/103 | 0/224 | 0/96 | 0/210 | 1/102 |
| Hypertensive crisisVascular disorders | 0/207 | 0/103 | 0/224 | 0/96 | 0/210 | 1/102 |
| Cerebral thrombosisNervous system disorders | 1/207 | 0/103 | 0/224 | 0/96 | 0/210 | 0/102 |
| Myocardial infarctionCardiac disorders | 0/207 | 0/103 | 0/224 | 0/96 | 1/210 | 0/102 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/207 | 0/103 | 0/224 | 0/96 | 1/210 | 0/102 |
| Intervertebral disc degenerationMusculoskeletal and connective tissue disorders | 0/207 | 0/103 | 0/224 | 0/96 | 1/210 | 0/102 |
| Event | Pitavastatin 1 mg | Pravastatin 10 mg | Pitavastatin 2 mg | Pravastatin 20 mg | Pitavastatin 4 mg | Pravastatin 40 mg |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 15/207 | 6/103 | 16/224 | 5/96 | 19/210 | 7/102 |
| InfluenzaInfections and infestations | 7/207 | 6/103 | 16/224 | 6/96 | 19/210 | 7/102 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/207 | 3/103 | 11/224 | 2/96 | 4/210 | 2/102 |
| ConstipationGastrointestinal disorders | 10/207 | 5/103 | 6/224 | 4/96 | 9/210 | 3/102 |
| NauseaGastrointestinal disorders | 5/207 | 5/103 | 6/224 | 1/96 | 3/210 | 0/102 |
| HeadacheNervous system disorders | 8/207 | 3/103 | 9/224 | 4/96 | 4/210 | 2/102 |
| Back painMusculoskeletal and connective tissue disorders | 6/207 | 3/103 | 9/224 | 1/96 | 3/210 | 2/102 |
| Upper respiratory infectionInfections and infestations | 3/207 | 4/103 | 2/224 | 1/96 | 3/210 | 3/102 |
| FatigueGeneral disorders | 2/207 | 4/103 | 0/224 | 0/96 | 4/210 | 0/102 |
| Age, Categorical(Participants) | Pitavastatin 1 mg | Pravastatin 10 mg | Pitavastatin 2 mg | Pravastatin 20 mg | Pitavastatin 4 mg | Pravastatin 40 mg | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| >=65 years | 207 | 103 | 224 | 96 | 210 | 102 | 942 |
| Age Continuous(years) | Pitavastatin 1 mg | Pravastatin 10 mg | Pitavastatin 2 mg | Pravastatin 20 mg | Pitavastatin 4 mg | Pravastatin 40 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 70.0 ± 4.60 | 70.5 ± 4.61 | 70.5 ± 4.49 | 69.9 ± 4.51 | 70.2 ± 4.10 | 70.2 ± 4.94 | 70.2 ± 4.49 |
| Sex: Female, Male(Participants) | Pitavastatin 1 mg | Pravastatin 10 mg | Pitavastatin 2 mg | Pravastatin 20 mg | Pitavastatin 4 mg | Pravastatin 40 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 118 | 54 | 124 | 48 | 121 | 42 | 507 |
| Male | 89 | 49 | 100 | 48 | 89 | 60 | 435 |
The record gives a start of Sep 2005, a primary completion of May 2006 and a completion of May 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin